Scientists Create Antibodies That Block Epstein-Barr Virus in 95% of People
Breakthrough antibodies completely prevent EBV infection in lab models, offering hope against virus linked to cancer and chronic disease.
Summary
Scientists at Fred Hutchinson Cancer Center have developed powerful antibodies that can block Epstein-Barr virus (EBV), which infects 95% of people worldwide and is linked to cancers and chronic diseases. Using mice engineered with human antibody genes, researchers created monoclonal antibodies targeting two viral proteins that help EBV attach to and enter immune cells. One antibody completely prevented infection in lab models with human-like immune systems. This breakthrough addresses a major challenge since EBV can bind to nearly all B cells in the immune system. The research is particularly promising for transplant patients who face serious complications from EBV reactivation due to immunosuppressive drugs.
Detailed Summary
Epstein-Barr virus affects 95% of people globally and contributes to various cancers, neurodegenerative conditions, and chronic illnesses. Despite its prevalence and health impact, developing effective treatments has been extremely challenging because EBV can bind to nearly every B cell in the human immune system.
Fred Hutchinson Cancer Center researchers made a significant breakthrough by using mice engineered to produce human antibodies. They identified ten monoclonal antibodies targeting two key viral proteins: gp350, which helps the virus attach to cells, and gp42, which enables cell entry. This approach overcomes previous limitations where non-human antibodies triggered unwanted immune reactions.
In laboratory testing, one gp42-targeting antibody completely blocked EBV infection in mice with human-like immune systems, while a gp350-targeting antibody provided partial protection. The research also revealed specific viral weak points that could guide future vaccine development.
This discovery has immediate relevance for transplant patients, who represent over 128,000 Americans annually. These individuals face heightened risk from EBV reactivation due to immunosuppressive medications, potentially leading to post-transplant lymphoproliferative disorders—a serious form of lymphoma. Currently, no targeted therapies exist to prevent these complications.
While promising, this research remains in early stages. The antibodies showed effectiveness in laboratory models, but human trials are needed to confirm safety and efficacy. The timeline for clinical availability remains uncertain, though the findings represent a crucial step toward addressing one of humanity's most common viral infections.
Key Findings
- One antibody completely prevented EBV infection in lab models with human immune systems
- Ten human-like antibodies identified targeting key viral entry proteins gp350 and gp42
- Research reveals specific viral weak points for future vaccine development
- Breakthrough addresses EBV's ability to infect nearly all B cells in immune system
- Potential therapy for 128,000+ annual transplant patients at high EBV risk
Methodology
This is a science news report from ScienceDaily covering peer-reviewed research published in Cell Reports Medicine. The source institution (Fred Hutchinson Cancer Center) is a reputable cancer research organization, lending credibility to the findings.
Study Limitations
The research is in early laboratory stages using mouse models, and human clinical trials have not yet begun. The timeline for therapeutic availability is unclear, and real-world effectiveness and safety in humans remain to be established through clinical testing.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.